Ligand Pharmaceuticals develops and acquires technologies used by pharmaceutical companies to discover and develop medicines. LGND has contributed its research and technologies for approved medicines that treat cancer, osteoporosis, fungal infections, and low blood platelets, among other conditions. Its partners have programs in clinical development targeting seizure, cancer, diabetes, cardiovascular disease, muscle wasting, liver disease, and kidney disease. Ligand's business model focuses on drug discovery, early-stage drug development, and product reformulation. Its pharmaceutical partners focus on late-stage development, regulatory management, and commercialization. Most recently, the company has contributed its technologies to the development of treatments for COVID-19. The company has 115 employees.
Argus ResearchThe Argus Research Team